To validate the level of TFAP2A in NSCLC, IHC and Western blot analyses was conducted to measure TFAP2A expression in tumour tissues, which demonstrated that the level of TFAP2A was higher in tumour tissues than in para-tumour tissues (Fig. 2A, B). This evidence concerns the gene TFAP2A and neoplasm.